Tanaz Meghjani

1 week ago | news.bloomberglaw.com | Ike Swetlitz |John Tozzi |Tanaz Meghjani

UnitedHealth Group Inc. is cutting commissions for brokers on some Medicare Advantage plans, according to documents reviewed by Bloomberg News, a move that appears designed to discourage agents from selling those plans. The decision comes as UnitedHealth grapples with high costs in Medicare Advantage that derailed its financial outlook and sent its share price tumbling. By steering brokers away from selling some of these plans, the insurance giant could ultimately lower its costs.

1 week ago | bloomberg.com | Ike Swetlitz |John Tozzi |Tanaz Meghjani

(Bloomberg) -- UnitedHealth Group Inc. is cutting commissions for brokers on some Medicare Advantage plans, according to documents reviewed by Bloomberg News, a move that appears designed to discourage agents from selling those plans. The decision comes as UnitedHealth grapples with high costs in Medicare Advantage that derailed its financial outlook and sent its share price tumbling. By steering brokers away from selling some of these plans, the insurance giant could ultimately lower its costs.

1 month ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.

1 month ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.

1 month ago | bloomberg.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

Industries | The Big Take By Robert Langreth Tanaz Meghjani Rachael Dottle May 28, 2025 The moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.